Journal of gastrointestinal oncology最新文献

{"title":"Prognostic and therapeutic significance of microscopic tumor focus in combined hepatocellular-cholangiocarcinoma: a multicenter pathological study.","authors":"Han Wang, Chun-Yan Xia, Xia Sheng, Yun Zhao, Hong-Zhen Chen, Wen-Ming Cong, Miao-Xia He, Hui Dong","doi":"10.21037/jgo-2026-0333","DOIUrl":"10.21037/jgo-2026-0333","url":null,"abstract":"<p><strong>Background: </strong>Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer lacking personalized pathological parameters. Microscopic tumor focus (MTF), a microscopic intrahepatic metastatic pattern, remains poorly characterized, with unclear prognostic and therapeutic relevance in cHCC-CCA. In this study, the detailed significance of MTF in cHCC-CCA was investigated.</p><p><strong>Methods: </strong>A multicenter study included 310 cHCC-CCA patients who underwent curative-intent hepatectomy. MTF was further graded by its number/distribution (MTF 0: absence of MTF; MTF 1: 1-5 proximal MTFs; MTF 2: >5 proximal MTFs/≥1 distal MTFs) and subclassified by its histology (HCC-type MTF; CCA-type MTF; HCC + CCA-type MTF).</p><p><strong>Results: </strong>MTF was detected in 48.1% (149/310) of patients (MTF 1: 43.2%, MTF 2: 4.8%; HCC-type MTF: 17.7%; CCA-type MTF: 20.6%; HCC + CCA type MTF: 9.7%). MTF positivity correlated with poorer recurrence-free survival (RFS) (median time: 0.23 and 0.89 years), early RFS, and overall survival (OS) (median time: 1.53 and 2.95 years, all P<0.001), with MTF 2 and HCC + CCA-type MTF predicting the worst prognosis. For MTF-positive patients, surgical margin >0.1 cm improved RFS, early RFS, and OS, while surgical margin had no effect on MTF-negative patients. Age, tumor diameter, microvascular invasion and perineural invasion independently predicted MTF (area under the curve =0.704); MTF histology was an independent prognostic factor for RFS, early RFS, and OS (all Harrell's concordance index >0.7).</p><p><strong>Conclusions: </strong>This study standardized the definition of MTF and confirmed its prognostic value in cHCC-CCA. MTF stratification based on its number/distribution and histology enables more precise prognostic assessment. The presence of MTF could guide individualized selection of surgical margin.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 3","pages":"163"},"PeriodicalIF":2.1,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13349950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148421535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic profile alterations as early indicators of gastrointestinal stromal tumors (GISTs) recurrence and imatinib resistance.","authors":"Allen Lin Luo, Allen Seylani, Yohannes Haile, Assal Sadighian, Sadaf Sadighian, Mark Agulnik","doi":"10.21037/jgo-2026-1-0182","DOIUrl":"10.21037/jgo-2026-1-0182","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract. Despite surgery and adjuvant imatinib for high-risk cases, recurrence remains high, often due to resistance from secondary kinase mutations. Imatinib is known to influence lipid metabolism in GIST and chronic myeloid leukemia (CML). This study evaluates metabolic trends in recurrent GIST post-resection to determine whether these biomarkers can signal resistance or early recurrence.</p><p><strong>Methods: </strong>This retrospective cohort study utilized de-identified data from the TriNetX database, comprising over 200 million patients across 172 healthcare systems in 18 countries. We examined total cholesterol, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), TG/HDL ratio, low-density lipoprotein cholesterol (LDL-C), hemoglobin A1c, body mass index (BMI), and thyroid-stimulating hormone (TSH) in 36 patients with recurrent GIST on imatinib.</p><p><strong>Results: </strong>Thirty-six patients were included in this study. Patients underwent resection an average of 25.9 months before recurrence. Total cholesterol increased significantly (R=0.92, P=0.03), while LDL-C showed a similar increasing trend (R=0.87, P=0.050). HDL-C decreased significantly between pre- and post-recurrence periods (P=0.03). BMI differed between pre- and post-recurrence periods (P=0.047). TG showed a strong positive correlation (R=0.93, P<0.05), and TSH a strong negative correlation (R=-0.88, P=0.049). After recurrence, patients began second- or third-line therapies.</p><p><strong>Conclusions: </strong>Patients with GIST recurrence demonstrated worsening metabolic profiles preceding recurrence-rising total cholesterol, LDL-C, TG, and BMI with declining HDL-C and TSH. Given imatinib's usual lipid-lowering effects, reversal of this pattern may reflect emerging resistance. These metabolic biomarkers could serve as early, non-invasive indicators of recurrence and guide timely intervention.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 3","pages":"139"},"PeriodicalIF":2.1,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13350592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148421519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a multivariable prediction model for tumor response and treatment tolerance based on body composition dynamics in rectal cancer undergoing neoadjuvant chemoradiotherapy.","authors":"Soohyeon Lee, Dong Hyun Kang, Tae Sung Ahn","doi":"10.21037/jgo-2026-0269","DOIUrl":"10.21037/jgo-2026-0269","url":null,"abstract":"<p><strong>Background: </strong>The treatment paradigm for locally advanced rectal cancer (LARC) is evolving toward total neoadjuvant therapy (TNT), emphasizing strategies to maximize tumor regression and enable organ preservation. Identifying host-related biomarkers that predict response to neoadjuvant chemoradiotherapy (CRT) has therefore become increasingly important. Although body composition has been associated with cancer prognosis, the distinct roles of skeletal muscle and adipose tissue dynamics in treatment tolerance and tumor response remain unclear. This study aimed to develop a multivariable prediction model for tumor response and treatment tolerance based on body composition dynamics during CRT.</p><p><strong>Methods: </strong>In this single-center retrospective cohort study conducted at a tertiary referral hospital, 138 patients with LARC who underwent neoadjuvant CRT were analyzed. Baseline and post-CRT body composition parameters (skeletal muscle and adipose indices at the L3 level) and clinicolaboratory variables were evaluated as predictors. The primary outcome was high TRG (tumor regression grade 3-4), and the secondary outcome was CRT-related adverse events (CRT-AEs). A multivariable logistic regression model was developed, with continuous variables standardized. Model performance was assessed using the area under the receiver operating characteristic curve (AUC) and decision curve analysis. Internal validation was performed using 1,000 bootstrap resamples.</p><p><strong>Results: </strong>High TRG was observed in 33.3% of patients. Multivariable analysis demonstrated that the absence of CRT-AEs, higher baseline subcutaneous fat index, and a smaller reduction in visceral fat during CRT were independently associated with high TRG (all P<0.05). In contrast, a greater reduction in skeletal muscle index (ΔSMI) during CRT was significantly associated with CRT-AEs. The prediction model incorporating these variables showed moderate discriminative performance (AUC =0.707; 95% CI: 0.619-0.794).</p><p><strong>Conclusions: </strong>Body composition appears to play compartment-specific roles during neoadjuvant CRT in rectal cancer. Skeletal muscle status primarily reflects treatment tolerance, whereas adipose tissue dynamics are more closely associated with tumor regression. These computed tomography (CT)-based metrics may serve as practical, noninvasive indicators to support risk stratification and personalized treatment strategies in the era of TNT.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 3","pages":"152"},"PeriodicalIF":2.1,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13350587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148421162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological and molecular profiling of sporadic synchronous multiple primary colorectal cancers: focus on microsatellite instability status.","authors":"Kai Lv, Hui Yang, Xiangpeng Xi, Yulin Liu, Yongbo Zhang, Jingbo Chen","doi":"10.21037/jgo-2026-1-0027","DOIUrl":"10.21037/jgo-2026-1-0027","url":null,"abstract":"<p><strong>Background: </strong>Sporadic synchronous multiple primary colorectal cancer (SSCRC) is uncommon, and its molecular features remain unclear. This study aimed to compare the clinicopathological and molecular characteristics of SSCRC with solitary colorectal cancer and to evaluate microsatellite instability (MSI) status across synchronous lesions.</p><p><strong>Methods: </strong>We retrospectively enrolled 46 patients with synchronous CRCs and 202 patients with solitary CRCs. MSI status was determined for each SSCRC lesion using polymerase chain reaction (PCR)-based testing. Additional clinicopathological variables and selected molecular features were also assessed.</p><p><strong>Results: </strong>Compared with solitary CRC, SSCRC index lesions were associated with more advanced clinicopathological features (all P<0.05). The proportion of deficient mismatch repair (dMMR) was significantly higher in SSCRC (19.6% <i>vs.</i> 5.0%, P=0.003). Overall survival was significantly worse in SSCRC (P=0.03), while disease-free survival did not differ significantly between groups. All SSCRC cases demonstrated concordant MSI status across lesions, with 19.6% classified as MSI-H and 80.4% as MSI-L/MSS.</p><p><strong>Conclusions: </strong>MSI status appears central to SSCRC biology and may aid prognostic stratification. SSCRC exhibits distinct clinicopathological and molecular characteristics relative to solitary CRC, supporting the need for lesion-level molecular evaluation to inform personalized management. In particular, patients with dMMR tumors may benefit from immunotherapy, highlighting the clinical importance of MSI assessment.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 3","pages":"161"},"PeriodicalIF":2.1,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13350015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148421598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and functional validation of SPON2 as a novel biomarker for the diagnosis and prognosis in hepatocellular carcinoma.","authors":"Wanrong He, Zehua He, Qingfeng Chen, Wei Lan, Guo Zhang","doi":"10.21037/jgo-2025-1-1003","DOIUrl":"10.21037/jgo-2025-1-1003","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is a major global health burden, with persistently low 5-year survival rates. The major clinical challenge in HCC lies in the lack of accurate biomarkers for early detection, prognostic evaluation, and prediction of tumor aggressiveness. This study aimed to identify reliable biomarkers for HCC diagnosis and outcome prediction, and to elucidate their functional relevance in tumor progression.</p><p><strong>Methods: </strong>Transcriptomic profiles of HCC and adjacent normal tissues, along with single-cell RNA sequencing (scRNA-seq) data from six HCC patients, were obtained from public databases. The differentially expressed genes (DEGs) were identified and functionally annotated. HCC tumor cell-specific genes were determined using the \"FindAllMarkers\" function. Genes that were upregulated in both HCC tissues and tumor cells were considered candidate biomarkers. Western blotting and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were used to assess spondin-2 (SPON2) and WNT-related gene expression. Cell counting kit-8 (CCK-8), 5-ethynyl-2'-deoxyuridine (EdU), as well as colony formation assays evaluated cell proliferation. Additionally, wound healing and transwell assays assessed migration and invasion capacities.</p><p><strong>Results: </strong>Integration of bulk transcriptomic and scRNA-seq datasets identified SPON2 as an HCC-specific biomarker. SPON2 showed favorable diagnostic accuracy in distinguishing HCC patients from healthy controls across four independent cohorts, and its elevated expression was linked to poor overall survival (OS) and increased metastatic potential. At the single-cell level, SPON2⁺ tumor cells showed higher invasion and migration scores. Functional assays confirmed that SPON2 promoted the proliferative, migrative, and invasive capacities of HCC cells <i>in vitro</i>. Moreover, SPON2 expression exhibited a robust positive correlation with the activation of WNT signaling pathway; while SPON2 knockdown suppressed WNT-related protein expression.</p><p><strong>Conclusions: </strong>Through integrative transcriptomic and single-cell analyses, SPON2 was identified as a robust HCC biomarker, aberrantly upregulated in HCC tissues and tumor cells, and predictive of shorter OS and enhanced metastatic potential. By activating the WNT signaling pathway, SPON2 enhances the proliferative, migrative, and invasive capacities of HCC cells, underscoring its pivotal role in tumor aggressiveness and providing insights into novel diagnostic and prognostic targets for HCC management.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 3","pages":"169"},"PeriodicalIF":2.1,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13349973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148421558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histopathologic, molecular, and clinical associations of fusion-positive gastrointestinal carcinomas.","authors":"Bennett A Caughey, Sean T Bannon, Chloe Simms, Haley Barnes, Leontios Pappas, Valentina Nardi, Dora Dias-Santagata, A John Iafrate, Ryan B Corcoran, Charlotte I Wang","doi":"10.21037/jgo-2026-1-0178","DOIUrl":"10.21037/jgo-2026-1-0178","url":null,"abstract":"<p><strong>Background: </strong>Comprehensive genomic profiling (CGP) is critical for optimal clinical care for gastrointestinal (GI) carcinomas. Outside of biliary tract cancers (BTCs), actionable fusions are uncommon and the utility of routine RNA-based fusion testing in GI cancers is not well established. We therefore evaluated routinely conducted RNA-based fusion testing in GI cancers at a single center.</p><p><strong>Methods: </strong>Patients with GI carcinomas who underwent RNA-based tissue fusion testing at Massachusetts General Brigham Cancer Institute were included. Tumors with fusions were characterized for molecular and histopathologic associations. <i>RSPO2/3</i> fusions in lower GI cancers were further characterized for survival and benefit from targeted therapy.</p><p><strong>Results: </strong>A total of 2,300 patients with GI carcinomas were included; 139 (6.0%) had a detected fusion. BTCs had the highest fusion incidence (13.7%), mostly <i>FGFR2</i>. Fusions were detected in 3.5-7.7% of colorectal cancer (CRC), pancreatic, esophagogastric adenocarcinoma (EGA), and small bowel carcinomas. Fusions of <i>BRAF</i>, <i>FGFR1-3</i>, <i>NTRK1/3</i>, <i>RSPO2/3</i>, and <i>NRG1</i> were rare (excepting <i>FGFR2</i> in BTCs) but observed in 3 or more cancer types. <i>RSPO2/3</i> fusions were the second most frequent overall (1.4%) and most frequent in CRC (2.6%) and small bowel cancers (5.8%). <i>RSPO2/3</i> fusions were associated with poorly differentiated and mucinous histology, preserved mismatch repair, wild-type (WT) <i>APC</i>, and either <i>KRAS</i> or <i>BRAF</i> V600E mutations, however were not associated with differential survival in CRC patients receiving BRAF targeted therapy. Fifteen of 20 (75%) pancreatic tumors with fusions were <i>KRAS</i> WT; in <i>KRAS</i>-mutated pancreatic cancer, most fusions were of unclear significance. Receipt of fusion targeted therapy was associated with longer survival in fusion positive pancreatic cancers and <i>FGFR2</i>-fusion positive BTCs. 20 fusions detected in EGA were heterogenous, including <i>FGFR</i>, <i>CLDN18</i>, and <i>RSPO2</i>.</p><p><strong>Conclusions: </strong>RNA-based testing identifies potentially actionable fusions in a clinically significant fraction of GI carcinomas. Patients who receive fusion targeted therapy during their clinical course demonstrate longer survival, supporting CGP including fusion testing for all patients. Lower GI cancers harboring <i>RSPO2/3</i> fusions have a distinct molecular and pathologic phenotype, but demonstrate few clinical differences. Several detected fusions had novel gene partners, highlighting the utility of partner-agnostic fusion testing.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 3","pages":"137"},"PeriodicalIF":2.1,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13350599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148421569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A hub for an herb: is STAT3 blockade at the epicenter of toosendanin-induced NCOA4-dependent ferritinophagy and ferroptosis in cancer cells?","authors":"Vadivel Ganapathy, Yangzom D Bhutia","doi":"10.21037/jgo-2026-1-0151","DOIUrl":"10.21037/jgo-2026-1-0151","url":null,"abstract":"","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 3","pages":"202"},"PeriodicalIF":2.1,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13350003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148421559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excess late mortality among long-term gastric cancer survivors following gastrectomy: a population-based cohort study.","authors":"Yi Fu, Jian Li","doi":"10.21037/jgo-2026-1-0141","DOIUrl":"10.21037/jgo-2026-1-0141","url":null,"abstract":"<p><strong>Background: </strong>Long-term survival after gastrectomy for gastric cancer (GC) is increasingly common, yet comprehensive understanding of late mortality patterns remains limited. This study aimed to quantify excess late mortality and identify associated risk factors among long-term GC survivors.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using the Surveillance, Epidemiology, and End Results (SEER) data (1992-2022) including 8,637 long-term GC survivors after gastrectomy. Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were calculated. Subgroup analyses were performed for all-cause, second malignant neoplasm (SMN)-related, and non-cancer health-related mortality. The relative-risk SMRs (RRSMRs) were estimated to assess effect modification by demographic and clinicopathological features.</p><p><strong>Results: </strong>The cohort experienced significantly elevated all-cause mortality [SMR =1.66, 95% confidence interval (CI): 1.61-1.70]. Non-cancer conditions became the predominant cause of late death (58.5%), surpassing recurrence (27.7%) and SMNs (11.7%). Younger age at diagnosis (15-49 years), radiotherapy, and chemotherapy were associated with particularly high excess mortality. Gastrointestinal diseases (SMR =2.30, 95% CI: 1.68-3.07) and infectious diseases (SMR =1.76, 95% CI: 1.53-2.00) showed the most pronounced elevations among non-cancer causes, while diabetes mortality risk was not significantly increased.</p><p><strong>Conclusions: </strong>Long-term GC survivors after gastrectomy face persistent excess mortality, primarily from non-cancer conditions. These findings highlight the need for risk-adapted survivorship care that extends beyond cancer surveillance to address late health risks in long-term GC survivors.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 3","pages":"142"},"PeriodicalIF":2.1,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13350656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148421493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of nomograms and predictive tools in gastrointestinal stromal tumor.","authors":"Bryant Morocho, Steve Kwon","doi":"10.21037/jgo-2026-1-0192","DOIUrl":"10.21037/jgo-2026-1-0192","url":null,"abstract":"","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 3","pages":"190"},"PeriodicalIF":2.1,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13350710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148421552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting adherence of imatinib in gastrointestinal stromal tumor-rise of the machines!","authors":"Thiru Prasanna, Desmond Yip","doi":"10.21037/jgo-2026-1-0145","DOIUrl":"10.21037/jgo-2026-1-0145","url":null,"abstract":"","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"17 3","pages":"186"},"PeriodicalIF":2.1,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13349999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148421582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}